2024, Número 5
<< Anterior Siguiente >>
Med Int Mex 2024; 40 (5)
Colangitis relacionada con IgG4
García FW, Villafuerte TI, Mexia AAL, Prado HD
Idioma: Español
Referencias bibliográficas: 47
Paginas: 295-304
Archivo PDF: 397.15 Kb.
RESUMEN
Antecedentes: La colangitis es una enfermedad fibroinflamatoria, casi siempre
por ictericia obstructiva, difícil de diferenciar por imagen de la colangitis esclerosante
primaria, su diagnóstico se basa en la elevación de las concentraciones séricas de
IgG4 y datos histopatológicos.
Objetivo: Describir el concepto y clasificación actual de la colangitis esclerosante
relacionada con la IgG4 según diferentes asociaciones, así como los aspectos patogénicos,
epidemiológicos, clínicos y terapéuticos.
Metodología: Búsqueda bibliográfica en las bases de datos GoogleScholar,
PubMed, Medline, LILACS y Scopus; se incluyeron artículos en inglés y en español.
Resultados: De la revisión bibliográfica se obtuvieron 60 artículos que cumplían
con los criterios de inclusión, dé estos se descartaron 13 por diversas razones (cartas
al editor, reporte de casos y revisiones duplicadas). Hasta la fecha no existen criterios
unificados en relación con el diagnóstico, clasificación y tratamiento de la colangitis
asociada con IgG4. Se encontrarron similitudes y diferencias en relación con los criterios
diagnósticos declarados por la Sociedad de Endoscopia de Japón y las Sociedades de
Gastroenterología de Europa y Estados Unidos. Una proporción importante de los casos
de colangitis esclerosante asociada con IgG4 tiene concentraciones elevadas de esta
inmunoglobulina y habitualmente responden satisfactoriamente a los corticosteroides.
Conclusiones: La colangitis esclerosante relacionada con IgG4 es una manifestación
biliar de la enfermedad relacionada con IgG4 de muy difícil diagnóstico que
suele confundirse con el colangiocarcinoma y otros tipos de colangitis. La colangitis
esclerosante relacionada con IgG4 tiene muy buen pronóstico y responde satisfactoriamente
a los corticosteroides.
REFERENCIAS (EN ESTE ARTÍCULO)
Umehara H, Okazaki K, Masaki Y, Kawano M, et al. Comprehensivediagnostic criteria for IgG4-related disease(IgG4-RD), 2011. Mod Rheumatol 2012; 22 (1): 21-30. doi:10.1007/s10165-011-0571-z
Okazaki K, Uchida K, Ikeura T, Takaoka M. Current conceptand diagnosis of IgG4-related disease in the hepato-biliopancreaticsystem. J Gastroenterol 2013; 48 (3): 303-14.doi: 10.1007/s00535-012-0744-3
Ohara H, Okazaki K, Tsubouchi H, et al. Clinical diagnosticcriteria of IgG4-related sclerosing cholangitis 2012. J HepatobiliaryPancreat Sci 2012; 19 (5): 536-542. doi:10.1007/s00534-012-0521-y
Nakazawa T, Kamisawa T, Okazaki K, Kawa S, et al. Clinicaldiagnostic criteria for IgG4-related sclerosing cholangitis2020: (Revision of the clinical diagnostic criteria forIgG4-related sclerosing cholangitis 2012). J HepatobiliaryPancreat Sci 2021; 28 (3): 235-242. doi: 10.1002/jhbp.913
Ghazale A, Chari ST, Zhang L, Smyrk TC, et al. ImmunoglobulinG4-associated cholangitis: clinical profile and responseto therapy. Gastroenterology 2008; 134 (3): 706-15. doi:10.1053/j.gastro.2007.12.009
Hirano K, Tada M, Isayama H, Yamamoto K, et al.Endoscopic evaluation of factors contributing to intrapancreaticbiliary stricture in autoimmune pancreatitis.Gastrointest Endosc 2010; 71 (1): 85-90. doi: 10.1016/j.gie.2009.08.008
Zen Y, Harada K, Sasaki M, et al. IgG4-related sclerosingcholangitis with and without hepatic inflammatory pseudotumor,and sclerosing pancreatitis-associated sclerosingcholangitis: ¿do they belong to a spectrum of sclerosingpancreatitis? Am J Surg Pathol 2004; 28 (9): 1193-1203.doi: 10.1097/01.pas.0000136449.37936.6c
Naitoh I, Kamisawa T, Tanaka A, et al. Clinical characteristicsof immunoglobulin IgG4-related sclerosing cholangitis:Comparison of cases with and without autoimmunepancreatitis in a large cohort. Dig Liver Dis 2021; 53 (10):1308-1314. doi: 10.1016/j.dld.2021.02.009
Tanaka A, Tazuma S, Okazaki K, Tsubouchi H, Inui K,Takikawa H. Nationwide survey for primary sclerosingcholangitis and IgG4-related sclerosing cholangitis inJapan. J Hepatobiliary Pancreat Sci 2014; 21 (1): 43-50.doi:10.1002/jhbp.50
Kanno A, Masamune A, Okazaki K, et al. Nationwide epidemiologicalsurvey of autoimmune pancreatitis in Japanin 2011. Pancreas 2015; 44 (4): 535-539. doi:10.1097/MPA.0000000000000325
Kamisawa T, Nakazawa T, Tazuma S, et al. Clinical practiceguidelines for IgG4-related sclerosing cholangitis. J HepatobiliaryPancreat Sci 2019; 26 (1): 9-42. doi:10.1002/jhbp.596
Tanaka A, Mori M, Kubota K, et al. Epidemiological featuresof immunoglobulin G4-related sclerosing cholangitis inJapan. J Hepatobiliary Pancreat Sci 2020; 27 (9): 598-603.doi:10.1002/jhbp.793
Tanaka A, Mori M, Matsumoto K, Ohira H, Tazuma S,Takikawa H. Increase trend in the prevalence and maleto-female ratio of primary biliary cholangitis, autoimmunehepatitis, and primary sclerosing cholangitis in Japan.Hepatol Res 2019; 49 (8): 881-889. doi:10.1111/hepr.13342
Tanaka A, Tazuma S, Okazaki K, et al. Clinical features,response to treatment, and outcomes of IgG4-relatedsclerosing cholangitis. Clin Gastroenterol Hepatol 2017; 15(6): 920-926.e3. doi: 10.1016/j.cgh.2016.12.038
Manganis CD, Chapman RW, Culver EL. Review of primarysclerosing cholangitis with increased IgG4 levels. WorldJ Gastroenterol 2020; 26 (23): 3126-3144. doi:10.3748/wjg. v26.i23.3126
Okazaki K, Uchida K, Ohana M, et al. Autoimmune-relatedpancreatitis is associated with autoantibodies and aTh1/Th2-type cellular immune response. Gastroenterology2000; 118 (3): 573-581. doi:10.1016/s0016-5085(00)70264-2
Khosroshahi A, Carruthers MN, Deshpande V, Unizony S,Bloch DB, Stone JH. Rituximab for the treatment of IgG4-related disease: lessons from 10 consecutive patients.Medicine (Baltimore) 2012; 91 (1): 57-66. doi: 10.1097/MD.0b013e3182431ef6
Zhao EJ, Cheng CV, Mattman A, Chen LYC. Polyclonal hypergammaglobulinaemia:assessment, clinical interpretation,and management. Lancet Haematol 2021; 8 (5): e365-e375.doi:10.1016/S2352-3026(21)00056-9
Zen Y, Kawakami H, Kim JH. IgG4-related sclerosing cholangitis:all we need to know. J Gastroenterol 2016; 51 (4):295-312. doi:10.1007/s00535-016-1163-7
Okazaki K, Uchida K, Miyoshi H, Ikeura T, Takaoka M, NishioA. Recent concepts of autoimmune pancreatitis and IgG4-related disease. Clin Rev Allergy Immunol 2011; 41 (2):126-138. doi:10.1007/s12016-010-8214-2
Wallace ZS, Naden RP, Chari S, Choi HK, et al; Membersof the ACR/EULAR IgG4-RD Classification Criteria WorkingGroup. The 2019 American College of Rheumatology/EuropeanLeague Against Rheumatism classification criteria forIgG4-related disease. Ann Rheum Dis 2020; 79 (1): 77-87.doi: 10.1136/annrheumdis-2019-216561
Ghazale A, Chari ST, Zhang L, et al. Immunoglobulin G4-associated cholangitis: clinical profile and response totherapy. Gastroenterology 2008; 134 (3): 706-715. doi:10.1053/j.gastro.2007.12.009
Huggett MT, Culver EL, Kumar M, et al. Type 1 autoimmunepancreatitis and IgG4-related sclerosing cholangitis is associatedwith extrapancreatic organ failure, malignancy, andmortality in a prospective UK cohort. Am J Gastroenterol2014; 109 (10): 1675-1683. doi:10.1038/ajg.2014.223
Lanzillotta M, Campochiaro C, Mancuso G, et al. Clinicalphenotypes of IgG4-related disease reflect different prognosticoutcomes. Rheumatology (Oxford) 2020; 59 (9):2435-2442. doi:10.1093/rheumatology/keaa221
Shiokawa M, Kodama Y, Yoshimura K, et al. Risk of cancer inpatients with autoimmune pancreatitis. Am J Gastroenterol2013; 108 (4): 610-617. doi:10.1038/ajg.2012.465
Moon SH, Kim MH, Lee JK, et al. Development of a scoringsystem for differentiating IgG4-related sclerosing cholangitisfrom primary sclerosing cholangitis. J Gastroenterol2017; 52 (4): 483-493. doi:10.1007/s00535-016-1246-5
Nakazawa T, Ohara H, Sano H, et al. Cholangiographycan discriminate sclerosing cholangitis with autoimmunepancreatitis from primary sclerosing cholangitis. GastrointestEndosc 2004; 60 (6): 937-944. doi:10.1016/s0016-5107(04)02229-1
Drazilova S, Veseliny E, Lenartova PD, Drazilova D, et al.IgG4-related sclerosing cholangitis: Rarely diagnosed, butnot a rare disease. Can J Gastroenterol Hepatol 2021; 2021:1959832. doi: 10.1155/2021/1959832
Naitoh I, Nakazawa T, Ohara H, et al. Endoscopic transpapillaryintraductal ultrasonography and biopsy in the diagnosisof IgG4-related sclerosing cholangitis. J Gastroenterol 2009;44 (11): 1147-1155. doi:10.1007/s00535-009-0108-9
Naitoh I, Nakazawa T, Hayashi K, et al. Comparison ofintraductal ultrasonography findings between primarysclerosing cholangitis and IgG4-related sclerosing cholangitis.J Gastroenterol Hepatol 2015;30(6):1104-1109.doi:10.1111/jgh.12894
Naitoh I, Nakazawa T. Classification and DiagnosticCriteria for IgG4-Related Sclerosing Cholangitis.Gut Liver.2022;2022;16(1): 28-36.doi:10.5009/gnl210116
Culver EL,Sadler Simpson D,et al.Elevated Serum IgG4 Levelsin Diagnosis, Treatment Response,Organ Involvement,andRelapse in a Prospective IgG4-Related Disease UK Cohort.Am J Gastroenterol.2016;111(5)733-743.doi:10.1038/ajg.2016.40
Taghavi SA, Majd SK, Sianati M, Sepehrimanesh M. Prevalenceof IgG-4-associated cholangiopathy based on serumIgG-4 levels in patients with primary sclerosing cholangitisand its relationship with inflammatory bowel disease.Turk J Gastroenterol 2016; 27 (6): 547-552. doi:10.5152/tjg.2016.16344
Tanaka A, Tazuma S, Nakazawa T, et al. No negative impactof serum IgG4 levels on clinical outcome in 435 patientswith primary sclerosing cholangitis from Japan HepatobiliaryPancreat Sci 2017; 24 (4): 217-225. doi:10.1002/jhbp.432
Muir AJ,Levy C,Janssen HLA,et al.Simtuzumb for PrimarySclerosing Cholangitis:Phase 2 Study Results With Insinghtson the Nature History of the Disease.Hepatology2019;69(2):684-698.doi:10.1002/hep.30237
Oseini AM, Chaiteerakij R, Shire AM, et al. Utility of serumimmunoglobulin G4 in distinguishing immunoglobulin G4associated cholangitis from cholangiocarcinoma. Hepatology2011; 54 (3): 940-948. doi:10.1002/hep.24487
Ohara H, Nakazawa T, Kawa S, et al. Establishment of aserum IgG4 cut-off value for the differential diagnosisof IgG4-related sclerosing cholangitis: a Japanese cohort.J Gastroenterol Hepatol 2013; 28 (7): 1247-1251.doi:10.1111/jgh.12248
Vosskuhl K, Negm AA, Frame T, et al. Measurement ofIgG4 in bile: A new approach for the diagnosis of IgG4-associated cholangiopathy. Endoscopy 2012; 44 (1): 48-52.doi:10.1055/s-0030-1256872
Nishino T, Oyama H, Hashimoto E, et al. Clinicopathologicaldifferentiation between sclerosing cholangitis withautoimmune pancreatitis and primary sclerosing cholangitis.J Gastroenterol 2007; 42 (7): 550-559. doi:10.1007/s00535-007-2038-8
Deshpande V, Sainani NI, Chung RT, et al. IgG4-associatedcholangitis: a comparative histological and immunophenotypicstudy with primary sclerosing cholangitis on liverbiopsy material. Mod Pathol 2009; 22 (10): 1287-1295.doi:10.1038/modpathol.2009.94
Löhr JM, Beuers U, Vujasinovic M, et al. EuropeanGuideline on IgG4-related digestive disease- UEG and SGF evidence-based recommendations.United European Gastroenterol J 2020; 8 (6): 637-666.doi:10.1177/2050540620934911
Kamisawa T, Shimosegawa T, Okazaki K, et al. Standardsteroid treatment for autoimmune pancreatitis. Gut 2009;58 (11): 1504-1507.doi10.1136/gut.2008.172908
Matsubachachi H, Ishiwatari H, Imai K, et al. Steroid therapyand steroid response in autoimmune pancreatitis. Int J MolSci 2019; 21 (1): 257. doi:10.3390/ijms21010257
Masaki Y, Shimizu H, Sato Nakamura T, et al. IgG4-relateddisease: diagnostic methods and therapeutic strategiesin Japan. J Clin Exp Hematop 2014; 54 (2): 95-101.doi:10.3960/jsIrt.54.95
Hart PA, Topazian MD, Witzig TE, et al. Treatment of relapsingautoimmune pancreatitis with immunomodulatorsand rituximab: the Mayo Clinic experience. Gut 2013; 62(11): 1607-1615. doi:10.1136/gutjnl-2012-302886
Carruthers MN, Topazian MD, Khosroshahi A, et al. Rituximabfor IgG4-related disease: a prospective, open-labeltrial. Ann Rheum Dis 2015; 74 (6): 1171-1177. doi:10.1136/annrheumdis-2014-206605
Bi Y, Hart PA, Law R, et al. Obstructive jaundice in autoimmunepancreatitis can be safely treated with corticosteroidsalone without biliary stenting. Pancreatology 2016; 16(3): 391-396. doi: 10.1016/j.pan.2016.03.017